In vitro evaluation of the effect of linezolid and levofloxacin on Bacillus anthracis toxin production, spore formation and cell growth

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 2, 2017, Pages 417-420

  Head, Breanne M ^a   Alfa, Michelle ^a,b   Sitar, Daniel S ^a   Rubinstein, Ethan ^a   Meyers, Adrienne F A ^a,c,d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b St Boniface Research Centre   (Canada)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; LEVOFLOXACIN; LINEZOLID; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIAL TOXIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAT SHOCK; IN VITRO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPOROGENESIS; BACTERIAL SPORE; BIOSYNTHESIS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY;

ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; DRUG SYNERGISM; LEVOFLOXACIN; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SPORES, BACTERIAL;

EID: 85014536013     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw427     Document Type: Article

References (20)

1. Inglesby T, O'Toole T, Henderson DA et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287: 2236-52.
2. Dai Z, Sirard JC, Mock M et al. The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. Mol Microbiol 1995; 16: 1171-81.
3. Price LB, Vogler A, Pearson T et al. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother 2003; 47: 2362-5.
4. Ortho-McNeil-Janssen Pharmaceuticals. Levaquin Full Prescribing Information 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf.
5. Li F, Nandy P, Chien S et al. Pharmacometrics-based dose selection of levofloxacin as a treatment for post-exposure inhalational anthrax in children. Antimicrob Agents Chemother 2010; 54: 375-9.
6. Swaney SM, Aoki H, Ganoza MC et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-5.
7. Louie A, VanScoy BD, Heine HS III et al. Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob Agents Chemother 2011; 56: 13-7.
8. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
9. Sopirala MM, Mangino JE, Gebreyes WA et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 4678-83.
10. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 1983; 11: 427-33.
11. Zelenitsky SA, Iacovides H, Ariano RE et al. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagnostic Microbiol Infect Dis 2005; 51: 39-43.
12. Biesta-Peters EG, Reij MW, Joosten H et al. Comparison of two optical-density-based methods and a plate count method for estimation of growth parameters of Bacillus cereus. Appl Environ Microbiol 2010; 76: 1399-405.
13. Joshi LT, Phillips DS, Williams CF et al. Contribution of spores to the ability of Clostridium difficile to adhere to surfaces. Appl Environ Microbiol 2012; 78: 7671-9.
14. Louie A, VanScoy BD, Brown DL et al. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrob Agents Chemother 2012; 56: 1229-39.
15. Carlson PE, Walk ST, Bourgis AETet al. The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe 2013; 24: 109-16.
16. Mathur T, Kumar M, Barman TK et al. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile. J Antimicrob Chemother 2011; 66: 1087-95.
17. Locher HH, Seiler P, Chen X et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 2014; 58: 892-900.
18. Jawetz E, Gunnison J. Antibiotic synergism and antagonism: an assessment of the problem. Pharmacol Rev 1953; 5: 175-92.
19. Frean J, Klugman KP, Arntzen L et al. Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide. J Antimicrob Chemother 2003; 52: 297-9.
20. Pharmacia and Upjohn. Zyvox. Pfizer Inc., NewYork, NY, USA, 2005. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4254b_02_05_KP% 20LinezolidFDAlabel52005.pdf.